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To the Editor:
Relapse in acute myeloid leukemia (AML) patients remains a
clinical challenge. The majority of AML patients who receive
induction treatment with combination chemotherapy achieve
clinicopathologic remission. However, a significant propor-
tion of these patients will relapse and succumb to chemore-
sistant disease [1]. The biological mechanisms that contribute
to relapsed AML are yet to be fully deciphered. Previous
studies investigating genetic contributions to AML disease
relapse included small numbers of patient samples and/or
focused on a small number of AML subtypes. These studies
have suggested that disease relapse is associated with founder
clone recurrence, subclonal expansion and/or the occurrence
of relapse-specific events (reviewed in [2]). To better under-
stand the somatic genomic changes that drive AML relapse,
we analyzed specimens (n= 120) from a clinically annotated
adult relapsed AML patient cohort [3] (Supplementary
Table S1, Supplementary Fig. S1) for somatic events. The
median age of the patient cohort was 50 years. All patients
received standard of care combination chemotherapy,
achieved complete remission and experienced disease relapse.
We first reanalyzed whole exome sequencing (diagnosis,
relapse and matched germlines) of 49 patients [3] in order to
capture the complete intragenic mutational burden (Fig. 1A,
Supplementary Tables S2 and S3). 21 patients had at least
one mutation lost at relapse. Twenty-three patients gained at
least one mutation at relapse. A subset of recurrent somatic
These authors contributed equally: Ross L. Levine, Ari Melnick
* Francine E. Garrett-Bakelman
fg5q@virginia.edu
1 Molecular Cancer Medicine Service, Human Oncology and
Pathogenesis Program, Memorial Sloan Kettering Cancer Center,
New York, NY, USA
2 Center for Clinical and Translational Science, The Rockefeller
University, New York, NY, USA
3 St. Giles Laboratory of Human Genetics of Infectious Diseases,
The Rockefeller University, New York, NY, USA
4 Department of Biochemistry and Molecular Genetics, University
of Virginia School of Medicine, Charlottesville, VA, USA
5 Cancer Biology and Genetics Program, Sloan Kettering Institute,
Memorial Sloan Kettering Cancer Center, New York, NY, USA
6 Division of Hematology/Oncology, Weill Cornell Medicine,
New York, NY, USA
7 Department of Medicine, University of Rochester, Rochester, NY,
USA
8 Division of Hematology and Oncology, University of
Pennsylvania Perelman School of Medicine, Philadelphia, PA,
USA
9 Department of Hematology, Erasmus MC Cancer Institute,
University Medical Center Rotterdam, Rotterdam, the Netherlands
10 Department of Internal Medicine III, University Hospital of Ulm,
Ulm, Germany
11 Department of Hematology, Oncology and Tumor Immunology,
Charité University Medicine Berlin, Berlin, Germany
12 Centre for Cancer Biology, University of South Australia and SA
Pathology, Adelaide, SA, Australia
13 Howard Hughes Medical Institute, Chevy Chase, MD, USA
14 Department of Data Science, Dana Farber Cancer Institute,
Boston, MA, USA
15 Department of Medicine, University of Virginia School of
Medicine, Charlottesville, VA, USA
16 University of Virginia Cancer Center, Charlottesville, VA, USA
Supplementary information The online version contains
















mutations were validated using orthogonal sequencing
(Supplementary Fig. S2; Supplementary Tables S4 and S5).
In addition to previously reported commonly mutated genes
[4, 5], we identified recurrently mutated genes (at least two
patients) that were stable or gained upon disease relapse.
Other mutations impacted chromatin remodeling (ARID1B,
BCORL1, CREBBP) and chromatid cohesion (ESPL1)
(Supplementary Tables S2 and S3). Previously, mutations
in chromatin-related genes at diagnosis were reported to
associate with higher rates of relapse [6].
To further understand the patterns of disease progression,
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Fig. 1 Genomic landscape of relapsed AML. A Comutation map for
the whole exome sequencing cohort. Each row is a gene and each
column a patient. Mutations were summarized by gene with the
exception of FLT3-ITD independently plotted. A cell is colored if the
corresponding gene is mutated in the corresponding patient. Every
gene that is mutated in at least three patients is included. The bar plot
shows the number of patients for which we detected a mutation in this
gene. Colors: brown = events detected in both diagnosis and relapse,
red = events only detected at diagnosis, and blue= events only
detected at relapse. B Co-mutation map in the targeted panel cohort.
Each cell is colored blue if the event is found stable between diagnosis
and relapse, orange if it significantly contracts between diagnosis and
relapse, and green if it significantly expands between diagnosis and
relapse.
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sparse whole genome sequencing in paired patient speci-
mens (n= 69; Supplementary Fig. S3). Results were com-
pared to clinical cytogenetics data and two specimens were
removed from the analysis due to discrepant findings.
44.7% of the 67 patients assessed (n= 30) had no detect-
able CNAs (Supplementary Table S6). In the remaining
patients, 34 events were gained and 14 were lost at relapse.
A high number of CNAs (three or more unrelated events)
was present in 14.9% of the patients (n= 10): three with
CNAs at both diagnosis and relapse, two with diagnosis-
specific events, and five with CNAs gained upon relapse.
Four of the five cases presented with “atypical” Complex
Karyotype disease and were not associated with TP53
mutations [7]. The remaining case exhibited a TP53 R273H
mutation that increased in allelic frequency from 0.0864 at
diagnosis to 0.281 at relapse with sparse sequencing data
revealing associated deletions at 5q and 17p among others
(Supplementary Fig. S3; Supplementary Tables S2, S3 and
S6). These karyotype changes are in agreement with a
previous report revealing changes in disease karyotypes
upon disease relapse [8].
To identify genetic variation associated with subclone
expansion or contraction during disease progression, we
implemented a targeted panel sequencing experiment on 63
matched diagnosis and relapse patient specimens. We
focused on 38 genes frequently mutated in AML, pre-
viously reported as oncogenic and likely-oncogenic somatic
events [6] (Supplementary Tables S2b and S7). Genetic
variation was considered significantly higher or lower if the
difference in allele fraction at relapse compared to diagnosis
was at least 0.05 VAF with a significance of p < 0.05 in a
Fisher statistical test (Supplementary Table S7). In more
than 50% of the patients that had a mutation in TP53, WT1
or the canonical FLT3-ITD, the mutant subclone expanded
at relapse compared to diagnosis (Fig. 1B). By contrast,
more than 50% of the subclones with MAPK activating
mutations (e.g., NRAS, PTPN11, and non-ITD FLT3) con-
tracted at relapse (Fig. 1B). Interestingly, in two patients, a
sub-clonal NRAS mutation at the time of diagnosis was lost
yet they gained another subclonal mutation in the same gene
at relapse. Mutations in CEBPA, DNMT3A, and NPM1 were
more often associated with a clonal fraction that was stable
between diagnosis and relapse (Fig. 1B).
We next determined inferred clonal evolution for each
patient of the targeted panel sequencing cohort between
diagnosis and relapse. Sixty of the patients could be divided
into three groups based on the greatest magnitude of change
(Fig. 2A; Supplementary Table S8). Group 1: Subclonal
changes: 31 patients exhibited significant change(s) in
subclonal composition (Supplementary Fig. S4; repre-
sentative examples in Fig. 2B and Supplementary Fig. S5).
Group 2: Clonal changes: 19 patients had either a conver-
sion of at least one subclonal fraction at diagnosis into a
clonal event at relapse or a de novo clonal event at relapse
(Supplementary Fig. S6; representative example in Fig. 2C.
and Supplementary Fig. S7). Group 3: Stable: ten patients
had no significant difference observed (Supplementary
Fig. S8; representative example in Fig. 2D). In three cases,
we could not reconcile the changes between the diagnosis
and relapse samples, suggesting either complex dynamics
not explained by the models, or the presence of uncommon
events outside of the targeted regions.
For three of the patients included in the study, serial
specimens were available for further clonal progression
assessment (Supplementary Tables S2c and S9). Results
were consistent with stable disease after first relapse
(AML_124 and AML_126; Supplementary Fig. S9) and the
possibility of further subclonal changes during disease
progression (AML_130; Fig. 2E). These data further sup-
port the occurrence of the proposed evolution models
observed throughout the disease time course.
We previously reported that shifts in DNA methylation
heterogeneity could classify patients who progress from
diagnosis to relapse [3]. We did not find any significant
association between the genomic evolution patterns and
DNA methylation heterogeneity groupings (Kruskal–Wallis
test, P= 0.433). Furthermore, patients’ age, sex, ELN
classification [9], treatment type, and time to relapse did not
significantly associate with the genomic evolution classifi-
cations (Kruskal–Wallis test, P > 0.05; Supplementary
Table S10).
Our work suggests that clonal dynamics can potentially
contribute to therapeutic resistance and disease progression.
Our evolution model predictions are similar to those ori-
ginally reported from mutational or cytogenetics data [2].
However, we cannot exclude the possibility that alternative
drivers of clonal composition were not detected in our data,
nor that different treatments will associate with different
clonal evolution patterns. Interestingly, the lack of associa-
tion between epigenetic and genetic evolution progression
patterns further supports an independent role for each process
during disease progression and the potential for parallel
approaches cells can take to disease diversification [3].
Our data suggests that subclonal changes could be
pathogenic in the etiology of AML relapse. Expansion of
clones with FLT3-ITD at relapse suggests that this enrich-
ment may contribute to disease progression potentially via
STAT5 activation, enhanced cell proliferation and/or dif-
ferentiation blockade [10]. Likewise, expansion of WT1
mutations in a subset of patients may contribute to tran-
scriptional dysregulation and impaired hematopoietic dif-
ferentiation associated with leukemogenesis [11] or to
resistance to treatment with DNA damage agents possibly
through disrupted TP53 stabilization and transcriptional
activity [12]. Finally, our data suggesting the loss of sub-
clones with MAPK activator gene mutations support
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previous findings consistent with NRAS mutations predis-
posing leukemic cells to cytarabine-induced differentiation
[13]. Changes in FLT3-ITD and karyotype also represent a
potential important clinical consideration for treatment of
relapsed disease with targeted [14] or PLK1-directed ther-
apy [15]. Importantly, the fact that actionable driver muta-
tions present at diagnosis can be lost or gained at relapse
supports a role for temporal monitoring to inform clinicians
about possible personalized targeted therapies to consider to
maximize clinical benefits in relapsed AML patients.
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Fig. 2 Clonal evolution during disease progression (targeted panel
sequencing cohort). A Partition of the targeted panel sequencing
cohort into each of the evolution patterns. Graphical representations
of examples of each evolution pattern identified: subclonal
(B: AML_001), clonal changes (C: AML_023), and stable changes
(D: AML_029) using a fish plot representation. The clone with the
highest VAF at a given time point was considered the parent clone.
Subclones were defined based on criteria detailed in the Clonal evo-
lution analysis subsection of “Materials and Methods”. The color key
for gene contributions to the pattern is located in the lower right corner
of the figure. E Graphical representation of AML_130 tumor evolution
pattern. Each vertical bar indicates a tumor sample collection time
point, with the time point (in days) along the x-axis.
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